Author: Ravi Shankar

SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Nathan J. “Nate” Hershman, ChFC®, CEPA, AAMS®, CPWA® CRPC®, has joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platforms to launch SteadRock Private Wealth. Hershman reported serving approximately $185 million in advisory, brokerage and retirement plan assets* and joins LPL from Edward Jones.

Based in North Canton, Ohio, SteadRock Private Wealth serves families, individuals approaching or living in retirement, and business owners, including those in the manufacturing sector. The practice helps clients consider the connections among their investments, retirement plans, business interests, charitable priorities and financial legacies.

“Behind a financial plan is a person, a family and a set of decisions that matter to them,” Hershman said. “I want to understand what clients are working toward, what concerns them and what they want their wealth to support before we begin discussing strategies.”

Hershman’s work combines an interest in understanding complex questions with a personal approach grounded in family, faith and integrity. For business owners, planning conversations may include preparing for a future transition, considering life after the business, and evaluating how a potential sale or succession could affect retirement, family and legacy priorities.

For families and retirees, the practice emphasizes understanding the life their financial resources are intended to support. Hershman begins with questions about clients’ circumstances, values and concerns, then helps them evaluate their options and revisit their plans as their lives change. When appropriate, he coordinates with clients’ tax and legal professionals.

“A useful advisory relationship needs room for honest conversations,” Hershman said. “Sometimes that means talking through a difficult decision or looking more closely at an assumption. My role is to listen, explain the considerations clearly and help clients think about how a decision fits into the larger picture.”

Why Nate Hershman Chose LPL

Hershman selected LPL to support his decision to establish an independent practice and shape how he serves clients. Through the affiliation, SteadRock Private Wealth has access to LPL’s technology, investment platform and business support resources.

“Building SteadRock gives me the opportunity to put my approach into practice under my distinctive brand that reflects my values,” Hershman said. “LPL provides resources to support that work while I focus on developing relationships and helping clients navigate the decisions ahead.”

“Nate has built SteadRock Private Wealth around a clear commitment to understanding what matters most to each client and helping them make thoughtful financial decisions,” said Ken Hullings, head of advisor recruiting and executive vice president of business development at LPL. “We’re excited to welcome Nate to LPL and support his vision for an independent practice grounded in personal relationships, candid conversations and comprehensive planning. We look forward to helping him build on that strong foundation and grow SteadRock for years to come.”

The SteadRock name reflects steadiness and a sound foundation, connecting Hershman’s love of the outdoors with his approach to planning. Outside of work, he enjoys photography, backpacking, camping and traveling with his family.

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. SteadRock Private Wealth and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1205997

-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure

-Encouraging preliminary clinical responses support option exercise, results planned for presentation at a major scientific conference

BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that it has exercised its option under its agreement with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”) to obtain an exclusive license to develop and commercialize Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, excluding China.

The CD7-targeted lentiviral platform is designed to deliver CAR payloads into the patient’s own immune cells, complementing Tempest’s existing lipid nanoparticle (LNP) delivery platform, for the in vivo generation of antigen-directed CAR-T cells. The lead program is SL4903, which Tempest is designating TPST-4903, a BCMA/GPRC5D dual-targeting candidate being studied in relapsed or refractory multiple myeloma (rrMM). By targeting two clinically validated targets in rrMM, TPST-4903 may reach a broader range of malignant plasma cells and limit tumor escape resulting from the loss or reduced expression of either target. The license also provides access to additional in vivo CAR-T candidates for potential development in blood cancers, solid tumors, and autoimmune conditions.

“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “We are encouraged by the emerging clinical data from the ongoing DELIVER-1 Phase 1 dose-escalation study of TPST-4903, which includes multiple myeloma patients with a substantial unmet need for new treatment options, such as those with extramedullary disease and those previously treated with CAR-T therapy. We look forward to sharing the detailed results with the scientific community.”

At the data cutoff for the current analysis, 13 patients in the DELIVER-1 study had received TPST-4903. The study population includes heavily pretreated patients with rrMM, including patients with extramedullary disease (EMD) and patients who previously received a BCMA-targeted CAR-T therapy. Tempest believes that preliminary observations of clinical activity and tolerability are encouraging and support further evaluation. The findings remain early, and additional follow-up is needed to characterize the benefit-risk profile. The data are expected to be presented at a major scientific conference.

“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease,” said Dr. Angel. “We continue to believe that these complementary platforms provide Tempest with the flexibility to match the delivery approach to the biology and treatment requirements of different cancers and autoimmune diseases.”

Tempest originally announced the exclusive option agreement with Senlang in September 2026. The license is subject to the financial obligations and development requirements set out in that agreement.

About TPST-4903, DELIVER-1, and Tempest’s CD7-Directed Lentiviral Platform

TPST-4903 is an investigational in vivo CAR-T therapy targeting BCMA and GPRC5D and delivered using a CD7-targeted lentiviral vector. DELIVER-1 (NCT07586709) is a single-center, open-label Phase 1 dose-escalation study enrolling patients with rrMM who have received at least two prior lines of therapy. The study is evaluating safety, tolerability, preliminary antimyeloma activity, and pharmacokinetic and pharmacodynamic characteristics. Tempest’s CD7-directed lentiviral platform, exclusively licensed from Senlang, includes a pipeline of clinical and preclinical-stage in vivo CAR-T programs, which are designed to selectively deliver CAR payloads to endogenous CD7-positive T cells and NK cells, enabling in vivo generation of antigen-directed CAR immune cells.

About Tempest Therapeutics

Tempest is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest’s lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.

About Hebei Senlang Biotechnology

Hebei Senlang Biotechnology Co., Ltd., is a clinical-stage cell therapy company focused on next-generation CAR-T technologies, with specialized expertise in CD7-targeted CAR-T development. Senlang has established end-to-end capabilities spanning CAR design, vector and plasmid development, GMP manufacturing and clinical trial execution, and is currently advancing multiple CD7 CAR-T programs, including a pivotal CD7 CAR-T clinical trial for relapsed or refractory T-cell lymphoblastic lymphoma/leukemia (“T-LBL/ALL”).

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended), concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest’s exclusive option and license with Senlang and the advancement, development, design and potential benefits of a BCMA/GPRC5D dual-targeting in vivo CAR-T therapy; the DELIVER-1 Phase 1 dose escalation trial, including the expected patient population, indications, number of patients, and expected assessments; the potential ability of BCMA/GPRC5D dual-targeting in vivo CAR-T therapy to enable broad tumor-antigen coverage, strengthen target-cell recognition, and support durable responses; the potential applicability of Tempest’s platform and product candidates across autoimmune and oncology indications; and Tempest’s ability to achieve its operational plans. All forward-looking statements in this press release are based on Tempest’s current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest’s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest.

Investor Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

AURORA, Ontario, Nov. 11, 2026 (GLOBE NEWSWIRE) — Magna International Inc. (TSX: MG; NYSE: MGA) is holding an Investor Day this morning in New York City, where it will showcase The Power of Magna. The presentation materials include new and compelling mid-term financial targets covering the period through 2030. The targets reflect Magna’s strategy to grow above market, execute with excellence and deploy capital with discipline.

Financial Targets:

• Organic sales growth: 2-4% above market on a compound annual basis through 2030
• Adjusted EBIT margin: 200+ basis points of margin improvement from 2026 through 2030
• Adjusted EPS: Compound annual growth of at least 15% through 2030
• Free cash flow (FCF): Average FCF conversion on adjusted net income of at least 85% over the 2027-2030 period
• Adjusted ROIC: Greater than 15% by 2030

Magna has solid visibility into its growth, with more than 90% of expected 2028 sales and more than 60% of expected 2030 sales supported by existing business and awarded programs. The company recently renewed its normal course issuer bid (NCIB) and intends to fully complete the repurchase of almost 26 million shares over the next 12 months.

“These targets reflect our confidence in Magna’s strategy, our capabilities and the opportunities that lie ahead,” said Swamy Kotagiri, Chief Executive Officer at Magna. “Against a modest growth environment, we believe we have a clear path to grow above market, continue expanding margins and create long-term value for our shareholders.”

Investor Day Webcast and Materials

Magna’s 2026 Investor Day begins today at 9 a.m. ET. The event will be webcast live, and participants can register at www.magna.com/investorday2026-virtual. The presentation materials are available at www.magna.com/company/investors, and a replay of the webcast will be available following the event.

INVESTOR CONTACT
Louis Tonelli, Vice President, Investor Relations
louis.tonelli@magna.com  │  905.726.7035

MEDIA CONTACT
Tracy Fuerst, Vice President, Corporate Communications & PR
tracy.fuerst@magna.com  │  248.761.7004

ABOUT MAGNA
Magna is one of the world’s largest automotive suppliers and a trusted partner to automakers in the industry’s most critical markets globally. With operations in 27 countries, we combine global scale with trusted reliability and proven execution. Backed by nearly seven decades of experience, we bring together deep manufacturing expertise with innovative vehicle systems to deliver performance, safety, and quality.
​
For further information about Magna (NYSE:MGA; TSX:MG), please visit www.magna.com or follow us on social.

NON-GAAP FINANCIAL MEASURES

In addition to financial measures presented in accordance with U.S. GAAP, we also use Non-GAAP financial measures in this press release. We believe the Non-GAAP financial measures are useful in analysis of the Company’s financial position, results and targets. In particular, management believes that Adjusted EBIT and Adjusted diluted earnings per share are useful measures in assessing the Company’s financial performance by excluding certain items that are not indicative of the Company’s core operating performance. Management also believes that Free Cash Flow is a useful measure in assessing the Company’s ability to generate cash to maintain operations and repay its debt. Please refer to our Management’s Discussion and Analysis of Results of Operations and Financial Position for three and nine month periods ended September 30, 2026, as well as our press release dated October 30, 2026 for a reconciliation of Non-GAAP measures to their most comparable U.S. GAAP measure. Non-GAAP financial measures do not have standardized meanings and may not be comparable to similar measures used by other companies in our industry. The presentation of Non-GAAP financial measures should not be considered in isolation, or as a substitute for the Company’s related financial results prepared in accordance with U.S. GAAP. 

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”). Any such forward-looking statements are intended to provide information about management’s current expectations and plans and may not be appropriate for other purposes. Forward-looking statements may include financial and other projections, as well as statements regarding our future plans, strategic objectives or economic performance, or the assumptions underlying any of the foregoing, and other statements that are not recitations of historical fact. We use words such as “may”, “would”, “could”, “should”, “will”, “likely”, “expect”, “anticipate”, “assume”, “believe”, “intend”, “plan”, “aim”, “forecast”, “outlook”, “project”, “potential”, “estimate”, “target” and similar expressions suggesting future outcomes or events to identify forward-looking statements. Unless otherwise indicated, all forward-looking statements in this press release are made as at November 11, 2026, and are subject to change after that date. 

The following table identifies the material forward-looking statements contained in this document, together with the material potential risks that we currently believe could cause actual results to differ materially from such forward-looking statements. Readers should also consider all of the risk factors which follow below the table:

Material Forward-Looking Statement	Material Potential Risks Related to Applicable Forward-Looking Statement
Light Vehicle Production	Light vehicle sales levels, including due to: A decline in consumer confidence Economic uncertainty Elevated interest rates and availability of consumer credit Deteriorating vehicle affordability Tariffs and/or other actions that erode free trade agreements Production deferrals, cancellations and volume reductions Production and supply disruptions Commodities prices Availability and relative cost of skilled labour
Total Sales Organic Sales GoM Sales Mix Segment Sales	Same risks as for Light Vehicle Production above Alignment of our product mix with production demand Supply disruptions, including as a result of semiconductor and memory (DRAM) chip shortages Customer concentration and growth in adjacent markets Pace of EV adoption, including North American electric vehicle program deferrals, cancellations and volume reductions Shifts in market shares among OEMs, vehicles and/or vehicle segments Shifts in consumer “take rates” for products we sell Relative currency values
Adjusted EBIT Margin Adjusted EBIT Margin Expansion Adjusted Diluted EPS Free Cash Flow Free Cash Flow Conversion	Same risks as for Total Sales and Segment Sales above Execution of critical program launches Operational underperformance Product warranty/recall risks Production inefficiencies Unmitigated incremental tariff costs Restructuring costs and/or impairment charges Inflation Ability to secure cost recoveries Price concessions Commodity cost volatility Scrap steel price volatility
Equity Income Adjusted ROIC	Same risks as Adjusted EBIT Margin above Risks related to conducting business through joint ventures Risks of doing business in foreign markets Legal and regulatory proceedings Changes in law
Share Repurchases Weighted Average Diluted Shares Outstanding	Same risks impacting Free Cash Flow above Ability to repurchase shares for cancellation, including due to normal course issuer bid rules, trading blackouts, and other factors

Forward-looking statements are based on information currently available to us and are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. While we believe we have a reasonable basis for making any such forward-looking statements, they are not a guarantee of future performance or outcomes. In addition to the factors in the table above, whether actual results and developments conform to our expectations and predictions is subject to a number of risks, assumptions, and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict, including, without limitation:

Macroeconomic, Geopolitical and Other Risks geopolitical crises and military conflicts; threats to free trade agreements; international trade disputes; planning and forecasting challenges; interest rates and availability of consumer credit; Risks Related to the Automotive Industry pace of EV adoption; North American EV program deferrals, cancellations and volume reductions; economic cyclicality; regional production volumes; deteriorating vehicle affordability; intense competition; Strategic Risks evolution of the vehicle; evolving business risk profile; technology and innovation; investments in mobility and technology companies; Customer-Related Risks customer concentration; market shifts; evolving OEM competitive landscape; dependence on outsourcing; consumer take rate shifts; nature of customer blanket purchase orders; potential OEM production-related disruptions; Supply Chain Risks supply chain disruptions; regional energy supply and pricing; financial condition of supply base; supplier claims; Manufacturing/Operational Risks product launch; operational underperformance; restructuring costs; impairments; skilled labour attraction/retention;

Pricing Risks quote/pricing assumptions; customer pricing pressure/contractual arrangements; commodity price volatility; scrap steel/aluminum price volatility; Warranty/Recall Risks repair/replacement costs; warranty provisions; product liability; IT Security/Cybersecurity Risks IT/cybersecurity breach; product cybersecurity breach; risks related to the use of artificial intelligence; Merger and Acquisition Risks inherent merger and acquisition risks; acquisition integration and synergies; Other Business Risks joint ventures; intellectual property; risks of doing business in foreign markets; tax risks; relative foreign exchange rates; returns on capital investments; financial flexibility; credit ratings changes; stock price fluctuation; Legal, Regulatory and Other Risks legal and regulatory proceedings; and changes in laws.

In evaluating forward-looking statements or forward-looking information, we caution readers not to place undue reliance on any forward-looking statement. Additionally, readers should specifically consider the various factors which could cause actual events or results to differ materially from those indicated by such forward-looking statements, including the risks, assumptions and uncertainties above which are:

• discussed under the “Industry Trends and Risks” heading of our Management’s Discussion and Analysis; and
• set out in our Annual Information Form filed with securities commissions in Canada, our annual report on Form 40-F filed with the United States Securities and Exchange Commission, and subsequent filings.

Readers should also consider discussion of our risk mitigation activities with respect to certain risk factors, which can be also found in our Annual Information Form. Additional information about Magna, including our Annual Information Form, is available through the System for Electronic Data Analysis and Retrieval + (SEDAR+) at www.sedarplus.ca, as well as on the United States Securities and Exchange Commission’s Electronic Data Gathering, Analysis and Retrieval System (EDGAR), which can be accessed at www.sec.gov.

BEIJING, Nov. 11, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase I clinical trial of ICP-B381, a novel bispecific ADC targeting PSMA and STEAP1, for the treatment of solid tumors, including prostate cancer.

ICP-B381 is InnoCare’s first bispecific ADC built on its proprietary ADC technology platform, comprising a humanized anti- PSMA/STEAP1 antibody conjugated to a potent proprietary payload via a next-generation irreversible linker. By engaging PSMA and STEAP1 simultaneously, ICP-B381 is designed to address heterogeneous tumor cell populations and reduce the risk of tumor escape, potentially benefiting a broader range of patients. In preclinical studies, ICP-B381 demonstrated robust and dose-dependent antitumor activity, outperforming the corresponding single-target PSMA-ADC and STEAP1-ADC at the same dose, with favorable tolerability.

PSMA and STEAP1 are significantly overexpressed in prostate cancer cells with limited expression in normal tissue, making them highly promising therapeutic targets, particularly in metastatic castration-resistant prostate cancer (mCRPC). Currently, no bispecific ADC targeting PSMA and STEAP1 has been approved for marketing globally.

Dr. Jasmine Cui, Co-Founder, Chairwoman, and CEO of InnoCare, said, “We are pleased that three of our novel ADC candidates have advanced into clinical development. We will accelerate the development of ICP-B381, to bring this differentiated treatment to prostate cancer patients as early as possible. Building on our proprietary ADC platform, we will continue to expand our pipeline of cutting-edge ADCs and deliver better, innovative treatment options to cancer patients worldwide.”

Prostate cancer is one of the most common malignancies among men worldwide, with an estimated 1.5 million new cases in 2024. It is the most frequently diagnosed cancer in men in nearly two-thirds of the world’s countries¹.

About InnoCare Pharma

InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information about InnoCare, please visit https://www.innocarepharma.com/en and follow us on LinkedIn.

Contact
Media	Investors
Chunhua Lu
86-10-66609879	86-10-66609999
chunhua.lu@innocarepharma.com	ir@innocarepharma.com

¹ International Agency for Research on Cancer (IARC). Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians, 2026.

Discussion highlights Vat-Ho’s oncology business development experience, his decision to join Akari and the potential of the Company’s novel PH1 payload platform

Watch the “What This Means” video here

TAMPA, Fla. and LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced its participation in a Virtual Investor “What This Means” segment featuring Vatnak Vat-Ho, the Company’s newly appointed Chief Business Officer.

During the segment, Mr. Vat-Ho discusses his background in oncology business development and strategic partnering, including experience with novel ADC payload technologies, and what attracted him to Akari. He highlights the potential of the Company’s PH1 payload, its differentiated dual mechanism of action and opportunities to advance its application across multiple ADC constructs.

Mr. Vat-Ho also shares his perspective on joining Akari as its lead candidate, AKTX-101, progresses toward clinical development. The discussion explores his priorities as Chief Business Officer, including advancing strategic collaborations, supporting investor engagement and translating the Company’s scientific progress into long-term value.

The segment concludes with Mr. Vat-Ho’s perspective on the evolving ADC landscape and the role of payload innovation in shaping the next generation of cancer therapies.

The Virtual Investor “What This Means” segment featuring Akari Therapeutics is now available here.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, AR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the potential characteristics and therapeutic applications of PH1 and PH1-based ADCs, the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com

Earns Gold Designation by Viqtory for Fourth Consecutive Year

GREENWICH, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, today announced that it has been recognized as a Military Friendly® Gold Employer for 2027 by Viqtory, a veteran-owned organization that evaluates companies based on their commitment to recruiting, retaining and advancing military talent.

This marks the fourth consecutive year XPO has earned national recognition as a Military Friendly Gold Employer. It reflects XPO’s ongoing commitment to supporting veterans, active-duty military personnel and military families through career opportunities, professional development and workplace programs.

“Veterans strengthen our organization through their leadership experience, adaptability and commitment to service,” said Tony Graham, executive vice president, revenue management and pricing, and a US Army and National Guard veteran. “We’re honored to receive this recognition again and remain committed to creating opportunities for veterans and military service members to build meaningful careers at XPO.”

Nearly 2,000 XPO employees in the US identify as veterans, serving in a wide range of roles across operations, maintenance, corporate functions and senior leadership positions. The company’s efforts to support the military community extend beyond hiring through employee recognition programs, veteran-focused initiatives and charitable partnerships that honor and serve those who have protected our freedom.

To explore career opportunities with XPO, visit: xpo.jobs/military.

About XPO
XPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company’s customer-focused organization efficiently moves 17 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 575 locations and 38,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn, Facebook, X, Instagram and YouTube.

Media Contact
Cole Horton
+1 203-609-6004
cole.horton@xpo.com

Proof of Concept Will Explore an Alternative to Costly Vehicle Patrols, with Potential to Redirect Budget and Personnel to Higher Priority Needs

Detroit, Michigan, Nov. 11, 2026 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), a developer and operator of AI-driven security and productivity solutions for enterprise clients, today announced that its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), will deploy a ROAMEO^™ autonomous security robot to a corrections facility for a proof of concept scheduled to run for 30 days. The deployment follows months of discussions and preparation with the corrections operator and will evaluate ROAMEO’s ability to perform autonomous perimeter patrols, reduce reliance on patrol vehicles and extend the reach of officers on duty. Based on discussions with the operator and various other factors, a successful evaluation could lead to the deployment of several dozen ROAMEO units.

“After 30 years in law enforcement, including my time at the FBI, I know how hard it is to maintain security when staffing runs thin,” said Troy McCanna, Chief Security Officer and Chief Revenue Officer at RAD and former FBI Special Agent. “I believe ROAMEO can make a real difference in corrections by extending the reach of the officers already on duty. Autonomous perimeter patrols can give corrections leaders more flexibility to assign highly trained officers where their judgment and experience matter most.”

ROAMEO can autonomously patrol fence lines and facility grounds for extended shifts, using its cameras and AI analytics to flag suspicious activity, including potential contraband deliveries. With SARA^™, RAD’s Speaking Autonomous Responsive Agent, ROAMEO can also engage individuals in conversation and deliver verbal warnings. Real time alerts can notify a security center or facility manager, while ROAMEO can move to an area of concern to give staff a clearer view of what is happening. By assuming routine perimeter patrol duties, ROAMEO could reduce reliance on vehicle fleets and their associated operating and maintenance costs while keeping officers available for assignments that require their training and judgment.

Corrections operators face persistent staffing shortages, heavy overtime demands and the ongoing threat of contraband entering their facilities. A January 2026 Congressional Research Service report found that the federal Bureau of Prisons spent $387.2 million on overtime in fiscal 2025¹. The report also described how staffing shortages can pull employees away from their primary duties and how fatigue from extended shifts can diminish officers’ observational skills. These pressures strain operating budgets and the personnel responsible for maintaining security every day.

“Corrections is vital public safety work, and I’m excited about what ROAMEO can do to support the people who do it every day,” McCanna added. “We have spent months preparing for this evaluation and have high expectations for what ROAMEO can demonstrate. We want this operator, and others facing the same pressures, to see a practical path to stronger perimeter security and a more effective use of their personnel and budgets.”

The Company invites corrections operators, enterprise security teams and channel partners to connect with its team to evaluate ROAMEO for their facilities and explore opportunities to expand patrol coverage while reducing the cost of security patrols.

About Artificial Intelligence Technology Solutions, Inc. (AITX)

AITX is a developer and provider of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and drive operational efficiency. Through its family of companies, including PURSUON, Inc. (formerly RAD-M), Robotic Assistance Devices, Inc. (RAD-I), Robotic Assistance Devices Residential (RAD-R), Robotic Assistance Devices Group (RAD-G), and Robotic Assistance Devices Lanka (Private) Limited (RAD Lanka), AITX develops and delivers a broad range of AI-driven technologies and services designed to transform security, automation, and operational workflows across multiple industries.

Through its primary subsidiary, RAD-I, AITX is redefining the nearly $50 billion U.S. security and guarding services industry² with its AI-driven Solutions-as-a-Service model. RAD solutions are specifically designed to deliver cost savings of between 35% and 80% compared to traditional manned security and monitoring, utilizing a suite of stationary and mobile autonomous systems that complement, and in many cases replace, human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are primarily developed in-house.

All of RAD’s solutions are designed to integrate with leading industry platforms and workflows, including an integration with Immix^®, a provider of central station and remote monitoring software.

The Company has completed a SOC 2 Type 2 examination covering the controls, system scope and review period described in the related report, a form of independent attestation frequently requested by enterprise and government clients that require documented data protection and compliance practices.

AITX is led by Steve Reinharz, CEO/CTO and founder of the Company and all subsidiaries, who brings decades of experience in the security services industry. The broader AITX leadership and its subsidiaries draw on deep expertise across security, law enforcement, and robotics innovation, supporting the Company’s ability to deliver practical and scalable solutions.

The Company’s solutions are deployed across a wide range of industries including enterprises, government, transportation, critical infrastructure, education, and healthcare.

To learn more, visit www.aitx.ai, www.radsecurity.com, www.pursuon.com, www.radgroup.ai, www.saramonitoring.ai, www.radlightmyway.com, and www.stevereinharz.com, or follow Steve Reinharz on X @SteveReinharz. Information contained on, or accessible through, the foregoing websites and social media accounts is not incorporated by reference into, and does not form a part of, this press release or any of the Company’s filings with the Securities and Exchange Commission.

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

This press release contains forward looking statements, including statements regarding the planned deployment of ROAMEO at a corrections facility; the anticipated timing, duration, scope and outcome of the 30 day proof of concept; management’s expectations regarding the evaluation and ROAMEO’s suitability for corrections applications; ROAMEO’s ability to perform autonomous perimeter patrols, identify suspicious activity and potential contraband deliveries, provide timely alerts, move to areas of concern and support security personnel; SARA’s ability to support conversational engagement and verbal warnings; the potential to reduce reliance on patrol vehicles, lower operating and maintenance costs and allow officers to focus on other assignments; the potential for a successful evaluation to lead to several dozen ROAMEO deployments with the operator; and the potential for additional orders, commercial deployments, recurring revenue or broader adoption within the corrections industry.

Forward looking statements are based on management’s current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others: the possibility that the proof of concept or related arrangements are delayed, modified, extended, suspended, canceled or terminated; delays or failures involving manufacturing, component availability, quality control, transportation, site preparation, route mapping, charging infrastructure, integration, commissioning or customer acceptance; the possibility that ROAMEO or SARA does not perform as expected or meet the operator’s requirements under actual operating conditions, including weather, lighting, terrain, obstacles, traffic, connectivity and charging conditions; interruptions, failures or limitations in autonomous navigation, detection, analysis, conversational engagement, communications or other hardware and software functions; missed events, false alerts, incorrect classifications, inappropriate or ineffective verbal responses, or delayed or unsuccessful notifications; requirements relating to facility security procedures, human supervision, safety, privacy, cybersecurity, data handling and applicable laws or regulations; the possibility that anticipated patrol coverage, staffing efficiencies or cost savings are not achieved or are offset by deployment, integration, maintenance, supervision, service or other operating costs; the possibility that evaluation results do not support expansion or cannot be replicated at other locations or at greater scale; customer budget constraints, procurement requirements, approval processes, competing priorities and changes in purchasing decisions; the Company’s ability to provide reliable service and support and scale production and deployment capabilities; competition and pricing pressure; the possibility that evaluations or deployments do not result in additional purchases, contract renewals, sustained recurring revenue or anticipated cash receipts; the Company’s ability to fund operations and fulfill customer commitments; the availability and terms of financing and its potential dilutive effects; the Company’s history of operating losses and its ability to continue as a going concern; and the other risks described in the Company’s most recent annual and quarterly reports, any amendments to those reports, and subsequent filings with the Securities and Exchange Commission, available at www.sec.gov.

The proof of concept is an evaluation. Its initiation or successful completion does not, by itself, establish a commitment to purchase, lease or deploy additional units. References to several dozen potential ROAMEO deployments reflect discussions concerning a possible expansion and should not be interpreted as a binding order, committed backlog or forecast of future revenue. Any expansion would depend on evaluation results, customer decisions, available funding, required approvals and mutually acceptable commercial arrangements. There can be no assurance that the evaluation will result in additional orders or deployments.

Actual cost savings and staffing efficiencies, if any, will depend on facility conditions, deployment configurations, service requirements, total operating costs and the extent to which existing patrol duties and vehicle expenses can be reassigned, reduced or eliminated. ROAMEO and SARA are intended to support security operations subject to human oversight and facility procedures. Their use does not guarantee the detection or prevention of every unauthorized activity, contraband delivery or security incident. Industry statistics referenced in this release provide general context and should not be interpreted as describing the participating operator’s staffing levels, expenditures or security incidents, or as estimates of savings achievable through this deployment.

Forward looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date of this release. The Company does not qualify for the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Except as required by law, the Company undertakes no obligation to update or revise any forward looking statement. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company.

For purposes of the Company’s disclosures, “Artificial Intelligence” refers to machine based systems designed to operate with varying levels of autonomy that, for a given set of human defined objectives, can make predictions, recommendations or decisions influencing real or virtual environments. In the context of the Company’s business, Artificial Intelligence is deployed primarily within the security services and property management industries to support functions such as detection, analysis, prioritization, communication and response related to safety, security and operational events.

The Company delivers these capabilities principally through its SARA^™ (Speaking Autonomous Responsive Agent) platform, which serves as the Company’s primary agentic artificial intelligence system. SARA is designed to receive and process video, audio and other sensor data, apply automated analysis and inference, and support actions in accordance with predefined operational objectives and human oversight. The Company’s Board of Directors oversees the Company’s deployment of Artificial Intelligence.

###

Doug Clemons, Chief Marketing Officer
248-270-8273
doug.c@radsecurity.com

---

¹ https://www.congress.gov/crs_external_products/R/PDF/R48826/R48826.3.pdf
² https://www.ibisworld.com/united-states/market-research-reports/security-services-industry/

DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) — (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company’s regulatory strategy in focus as it prepares for a randomized Phase 3 study.

NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.

The company also plans to discuss NEO100-012, a proposed multicenter, randomized, controlled Phase 3 trial comparing NEO100 against investigator’s-choice standard-of-care chemotherapy. Overall survival would serve as the primary endpoint.

Phase 2a results provide the foundation for the FDA discussion

The company’s accelerated approval ambitions follow results announced August 12, 2026, from the Phase 2a portion of its NEO100-01 study.

According to NeOnc, the study achieved a six-month progression-free survival (PFS-6) rate of 48.9%, with a 95% confidence interval of 26.3% to 68.1%. This exceeded the protocol-defined 20% historical benchmark for standard-of-care treatment, with a reported one-sided p-value of 0.0047.

The efficacy analysis included 24 patients with IDH1-mutant tumors, 21 of whom had grade 4 disease. Five patients remained on treatment at the interim database lock on June 24, 2026.

NeOnc also reported that independent central MRI assessments were used and that no treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events, or discontinuations due to treatment-related adverse events had occurred.

These results offer an encouraging signal, particularly given the limited treatment options available to patients with recurrent high-grade astrocytoma.

Why the accelerated approval strategy matters

The FDA’s Accelerated Approval Program allows certain treatments for serious conditions to receive earlier approval based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit.

For cancer treatments, progression-free survival can potentially serve as an endpoint supporting regulatory consideration, depending on the disease, treatment effect and strength of the supporting evidence.

NeOnc’s NEO100-012 may be underway, with enrollment ongoing, when any potential NDA is submitted. The trial’s final overall survival analysis would then be intended to confirm clinical benefit and support conversion to traditional approval.

A separate question concerns the company’s proposed scientific bridge between published perillyl alcohol data and its proprietary intranasal NEO100 formulation.

The FDA is also expected to discuss the adequacy of the existing nonclinical safety package and whether NEO100 could qualify for Breakthrough Therapy designation.

Insider purchases add another dimension

There is also a notable corporate insider development worth considering.

In its November 5, 2026, third-quarter business update, NeOnc reported that Executive Chairman and CEO Amir Heshmatpour and Dr. Thomas C. Chen purchased a combined 160,016 shares of company common stock for approximately $629,000 in open-market transactions following the Phase 2a results. The company said the purchases were made using personal funds.

Heshmatpour has continued buying shares in the open market, purchasing 80,000 shares for approximately $269,082 across November 5, 6 and 9, according to SEC Form 4 filings. The transactions included 30,000 shares at a weighted average price of $3.167 on November 5, another 40,000 at $3.3875 on November 6, and 10,000 shares at $3.86 on November 9. The purchases were made with personal funds, and no new shares were issued by the company in connection with the transactions.

The latest purchases bring Heshmatpour’s reported 2026 open-market buying to 271,000 shares, representing approximately $1.11 million, according to NeOnc, and are worth mentioning because they occurred after the August clinical announcement and before the latest regulatory development.

Short interest points a squeeze setup

Insider buying can provide an additional indication of management confidence, particularly when executives purchase shares in the open market rather than receiving equity compensation.

Market data for October 30, 2026, showed approximately 920,631 shares sold short, representing approximately 7.03 days to cover, well above the coveted 5 days to cover threshold, and several sites are reporting even larger amounts, which could be an even more powerful force.

November and January bring important catalysts

The FDA meeting is not the company’s only upcoming milestone.

NeOnc announced in its November 5 third-quarter update that it expects to present updated NEO100 Phase 1/2a results and NEO212 Phase 1 data at the Society for Neuro-Oncology’s annual meeting on November 13, 2026.

The NEO100 presentation will include updated results from the clinical study and compassionate-use experience.

Additional information from these presentations could help investors assess whether the August topline findings remain consistent with the updated clinical dataset.

The company also has a separate regulatory milestone involving NEO212, its oral investigational drug candidate. An FDA End-of-Phase 1 Type B meeting concerning NEO212 is scheduled for November 17, 2026, according to the company’s September announcement.

For NEO100, the early January 2027 meeting will be the next major regulatory event, with the company saying it expects to provide an update after receiving and reviewing the FDA’s official meeting minutes, as the content of those minutes could be more important than the announcement that the meeting itself has been scheduled.

About 247MarketNews

In today’s fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Renk Group AG: Doreen Nowotne, Acquisition

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them,
11. Nov 2026 / 14:30 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name

Title
First name	Doreen
Last name	Nowotne

2. Reason for the notification

a) Position / status

Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

Renk Group AG

b) LEI

894500H8CNSZ53EI6K63

4. Details of the transaction(s)

a) Description of the financial instrument

Type	Share
ISIN	DE000RENK730

b) Nature of the transaction

Acquisition

c) Price(s) and volume(s)

Price(s)	Volume(s)
34.00 EUR	24,650.00 EUR

d) Aggregated information

Price	Aggregated volume
34.00 EUR	24,650.00 EUR

e) Date of the transaction (CET/CEST)

09.11.2026

f) Place of the transaction

Name	Tradegate
MIC	XGAT

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

ATLANTA, GA, Nov. 11, 2026 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), a global provider of AI-powered trust, identity, and security solutions, today announced Provisional Patent # 64/195,409 issued by the United States Patent and Trademark Office on November 9, 2026. 

The new patent filing, together with existing issued patents, protects a new Trust Stamp product that ensures Knowing ConsentTM for transactions initiated by Agentic-AI. The product utilizes proprietary processes protected by existing issued patents together with the newly issued Provisional Patent and is ready for immediate use.  

Trust Stamp’s agentic-authorization distinguishes an AI-Agent initiating a request from the human account owner and ensures that the account holder consents to each transaction in a fast, secure, low friction process. The authorization flow can be initiated by the AI-Agent or the financial institution.  

Trust Stamp CEO, Gareth N. Genner commented, “This human-centric utility is ready to use unlike the various Agent-Identity concepts being proposed in the media. Trust Stamp already has over one hundred banks integrated to our Orchestration Layer. This biometric-backed authorization gives financial institutions a way to add a live, low friction and customer-centered approval step to Agent-Initiated activity either through the Orchestration Layer or via a single API call. The utility can be implemented in a matter of days, all within the institution’s existing access and transaction policies and with no significant changes to the flow of their authentication process.” 

Inquiries: 

Additional information and requests for the Company’s Knowing ConsentTM Whitepaper can be accessed at https://truststamp.ai/solutions/agentic-authentication. 

Investor Communications: shareholders@truststamp.ai 

Financial Institution Inquiries: agowasack@truststamp.ai 

About Trust Stamp 

Trust Stamp is a global provider of AI-powered services for use in multiple sectors including banking and finance, regulatory compliance, government, healthcare, real estate, communications, and humanitarian services. Its technology empowers organizations via advanced solutions that reduce fraud, tokenize and secure assets and data and securely authenticate users while protecting personal privacy, reduce friction in digital transactions, and increase operational efficiency, enabling customers to accelerate secure financial inclusion and reach and serve a broader base of users worldwide. 

With team members from over twenty nationalities in ten countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI). 

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks  

All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.